FeesSafety
Pluang+

Nuvectis secures $140M funding, advances two late-stage drug candidates in oncology and rare diseases.

Company Fundamentals
22 Nov 2026, 22:15 WIB
The Motley Fool
View Source
Bullish
Nuvectis secures $140M funding, advances two late-stage drug candidates in oncology and rare diseases.

Nuvectis announced a $140 million cash reserve supporting operations through mid-2029 after licensing two late-stage drug candidates from Haisco Pharmaceutical Group. The lead drug, NXP-100, offers a convenient once-daily oral treatment for the rare blood disorder PNH, potentially outperforming twice-daily alternatives. The second candidate, NXP-200, shows promising results in treating recurrent high-grade glioma brain tumors, including patients previously treated. The company is focused on FDA regulatory pathways and international partnerships to advance clinical trials and regulatory approvals in the US and China.

Nuvectis' $140 million cash reserve supports operations through mid-2029, providing context for readers interested in the company. For readers following the health sector, here is Pluang's market snapshot as of Nov 23, 2026 03:02 WIB: out of 150 priced US health stocks tradable on Pluang, 31 rose and 117 fell. Notable movers include HIMS (Hims and Hers Health Inc) at USD 14.60 with a 1-day change of -8.86%, TLRY (Tilray Brands Inc) at USD 1.89 down 8.70%, and SANA (Sana Biotechnology Inc) at USD 1.59 down 8.62%.

More News

Regional Management Q3 revenue hits $179M; auto loans grow 25%, bank partnerships boost margins.

Regional Management Q3 revenue hits $179M; auto loans grow 25%, bank partnerships boost margins.

Regional Management reported $179 million in revenue for Q3 2026, driven by expanding bank partnerships and a 25% year-over-year increase in auto-secured loans. The company is tightening credit on high-risk digital loans and shifting focus to auto-se...

Company Fundamentals
Bullish
1 hour ago
Everforth's Q3 revenue tops $1B; cybersecurity bookings surge 40% amid rising AI adoption.

Everforth's Q3 revenue tops $1B; cybersecurity bookings surge 40% amid rising AI adoption.

Everforth reported $1.03 billion in revenue for Q3 2026, surpassing company guidance. The firm sees enterprise software as the key channel for AI deployment, with strong growth in cybersecurity and risk bookings, up over 40% year-to-date due to incre...

Company Fundamentals
Bullish
1 hour ago
US Treasury opens door for Nvidia CEO Jensen Huang's return amid export control probe.

US Treasury opens door for Nvidia CEO Jensen Huang's return amid export control probe.

US Treasury Secretary Scott Bessent initially called for Nvidia to hire an external CEO amid export control violation allegations. However, he later indicated former CEO Jensen Huang, who resigned amid scandal, could return. The Treasury is investiga...

Market News
Bearish
1 hour ago
Newtek's Q3 net interest income hits $18.9M, up 30% YoY, driven by digital banking and zero-cost referrals.

Newtek's Q3 net interest income hits $18.9M, up 30% YoY, driven by digital banking and zero-cost referrals.

Newtek reported a record quarterly net interest income of $18.9 million in Q3 2026, a 30% increase year-over-year, fueled by higher yields on commercial loans and longer holding periods for SBA loans. The company leverages its digital NewTracker plat...

Company Fundamentals
Bullish
1 hour ago
One Stop raises 2026 revenue growth forecast to 40% amid expanding multiyear contracts in rugged edge computing.

One Stop raises 2026 revenue growth forecast to 40% amid expanding multiyear contracts in rugged edge computing.

One Stop Systems raised its full-year 2026 revenue growth guidance to about 40%, driven by expanding multiyear platform contracts in rugged edge computing across healthcare, aerospace, and defense sectors. The company increased its active multiyear p...

Company Fundamentals
Bullish
1 hour ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App